GSK plc
GSK
$46.63
-$0.47-1.00%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 42.05B | 40.96B | 40.23B | 40.10B | 39.71B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.05B | 40.96B | 40.23B | 40.10B | 39.71B |
| Cost of Revenue | 11.57B | 11.58B | 11.29B | 11.30B | 10.95B |
| Gross Profit | 30.49B | 29.38B | 28.94B | 28.81B | 28.76B |
| SG&A Expenses | 11.67B | 11.45B | 11.46B | 11.37B | 11.25B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -682.11M | -620.26M | -473.30M | -438.07M | -1.09B |
| Total Operating Expenses | 30.85B | 30.46B | 30.06B | 30.00B | 28.77B |
| Operating Income | 11.20B | 10.50B | 10.17B | 10.11B | 10.94B |
| Income Before Tax | 9.21B | 5.98B | 5.35B | 4.41B | 4.16B |
| Income Tax Expenses | 1.25B | 823.22M | 742.23M | 666.49M | 563.49M |
| Earnings from Continuing Operations | 7.96K | 5.16K | 4.60K | 3.74K | 3.59K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -745.63M | -729.05M | -623.14M | -481.12M | -429.32M |
| Net Income | 7.22B | 4.43B | 3.98B | 3.26B | 3.17B |
| EBIT | 11.20B | 10.50B | 10.17B | 10.11B | 10.94B |
| EBITDA | 15.47B | 15.00B | 13.93B | 13.53B | 13.97B |
| EPS Basic | 1.78 | 1.09 | 0.97 | 0.80 | 0.78 |
| Normalized Basic EPS | 1.44 | 1.33 | 1.30 | 1.32 | 1.46 |
| EPS Diluted | 1.75 | 1.07 | 0.96 | 0.79 | 0.77 |
| Normalized Diluted EPS | 1.42 | 1.31 | 1.29 | 1.31 | 1.44 |
| Average Basic Shares Outstanding | 16.27B | 16.31B | 16.33B | 16.31B | 16.28B |
| Average Diluted Shares Outstanding | 16.49B | 16.53B | 16.55B | 16.52B | 16.49B |
| Dividend Per Share | 0.84 | 0.82 | 0.79 | 0.78 | 0.77 |
| Payout Ratio | 45.82% | 72.89% | 79.74% | 95.77% | 96.19% |